The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | PBCAR0191 allo-CAR-T for ALL and NHL: preliminary findings
Bijal Shah, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the initial findings of the phase 1 trial (NCT03666000) of PBCAR0191, an anti-CD19 allogeneic CAR T-cell product designed to reduce the risk of graft-versus-host disease (GvHD), which is a limitation of allogeneic products, in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Additionally, Dr Shah mentions the next steps in the dose-escalation study of safety of PBCAR0191. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
